August 08, 2023 08:00 ET – Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma -Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated with a safety profile consistent with prior clinical trials – -VIRAGE remains on […]
May 11, 2023 22:48 ET – Prosigue la inscripción de pacientes en VIRAGE, el ensayo clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Presentación de datos del ensayo clínico de fase 1b/2a en curso de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células
May 11, 2023 08:00 ET – Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Presented data from the ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients at the 33rd European Congress of
May 04, 2023 08:00 ET ROCKVILLE, Maryland, May 04, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que tiene previsto realizar una teleconferencia el jueves, 11 de mayo de
– Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) – April 13, 2023 08:00 ET ROCKVILLE, Md., April 13, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer
March 31, 2023 00:33 ET – Dosis al primer paciente de VIRAGE, un ensayo clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Dosis al primer paciente del ensayo de fase 1 patrocinado por investigadores de VCN-01 en pacientes con tumores cerebrales – – Presentación
March 30, 2023 08:00 ET – Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 clinical trial of VCN-01 for patients with brain tumors – – Presented positive safety
Title: Sidoti Virtual Conference Presentation Date: Thursday, December 8, 2022 Time: 9:15 AM ET Link: Click here
Sidoti Virtual Conference Presentation Read More »
November 10, 2022 16:45 ET –Reported encouraging clinical data supporting the differentiated mode-of action of Theriva’s novel oncolytic adenovirus (OV) platform– –Received clearance from the Federal Drug Administration (FDA) and Spanish Competent Authority (AEMPS) for the planned Phase 2 clinical trial of systemically administered VCN-01 in Pancreatic Ductal Adenocarcinoma (PDAC) patients– –Reported positive safety and
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11,
